JNU-0921

JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8+ T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity[1].

Product Specifications

UNSPSC

12352005

Target

TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jnu-0921.html

Purity

99.77

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC(C2=NOC(C3=CC(C=CC=C4)=C4C=C3)=N2)=CC=C1

Molecular Formula

C19H12N2O3

Molecular Weight

316.31

References & Citations

[1]Liu L, et al. Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8+ T cells in cis and in trans. Sci Adv. 2024 Aug 23;10 (34) :eadp8647.